ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ:ACAD
Want to see ACAD full AI Analyst Report?
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of $3.66B. The enterprise value is $3.31B.
Market Cap$3.66B
Enterprise Value$3.31B
Share Statistics
ACADIA Pharmaceuticals has 171,235,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding171,235,870
Owned by Insiders23.27%
Owned by Institutions3.86%
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 8.07%.
Return on Equity (ROE)0.32
Return on Assets (ROA)0.25
Return on Invested Capital (ROIC)8.07%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee1.64M
Profits Per Employee598.77K
Employee Count653
Asset Turnover0.69
Inventory Turnover2.57
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 260.9. ACADIA Pharmaceuticals’s PEG ratio is 0.17.
PE Ratio260.9
PS Ratio4.22
PB Ratio3.69
Price to Fair Value3.69
Price to FCF43.02
Price to Operating Cash Flow28.57
PEG Ratio0.17
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 1.07B and earned 391.00M in profits. Earnings per share was 2.32.
Revenue1.07B
Gross Profit982.51M
Operating Income104.81M
Pretax Income138.90M
Net Income391.00M
EBITDA138.90M
Earnings Per Share (EPS)2.32
Cash Flow
In the last 12 months, operating cash flow was 123.49M and capital expenditures 88.94M, giving a free cash flow of 212.43M billion.
Operating Cash Flow123.49M
Free Cash Flow212.43M
Free Cash Flow per Share1.24
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-2.68%
50-Day Moving Average22.35
200-Day Moving Average23.72
Relative Strength Index (RSI)51.34
Average Volume (3m)1.81M
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is Aug 11, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 4.07%
Current Ratio3.83
Quick Ratio3.71
Debt to Market Cap<0.01
Net Debt to EBITDA-0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid -252.10M in taxes.
Income Tax-252.10M
Effective Tax Rate-1.81
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 31.66, with an EV/FCF ratio of 41.82.
EV to Sales4.10
EV to EBITDA31.66
EV to Free Cash Flow41.82
EV to Operating Cash Flow40.04
Balance Sheet
ACADIA Pharmaceuticals has $851.46M in cash and marketable securities with $50.79M in debt, giving a net cash position of $800.66M billion.
Cash & Marketable Securities$851.46M
Total Debt$50.79M
Net Cash$800.66M
Net Cash Per Share$4.68
Tangible Book Value Per Share$6.61
Margins
Gross margin is 91.47%, with operating margin of 9.78%, and net profit margin of 36.49%.
Gross Margin91.47%
Operating Margin9.78%
Pretax Margin12.96%
Net Profit Margin36.49%
EBITDA Margin12.96%
EBIT Margin12.96%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is $32.77, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.77
Price Target Upside47.81% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast9.93%
EPS Growth Forecast61.40%